58 results about "Hepatic encephalopathy" patented technology

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. According to the application of lanthanum carbonate in preparation of the medicine for treating hepatic encephalopathy, the medicine comprises lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate, the medicine is ground and then mixed with food to prepare a medicine mixture, and the medicine mixture is prepared into the medicine for treating hepatic encephalopathy. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%. According to the application, the blood ammonia is reduced based on the glutaminase, the hepatic encephalopathy is reversed by reducing the blood ammonia and systemic inflammation, and the liver function is recovered by regulating the inflammation, so that the hepatic encephalopathy is favorably cured, a good treatment effect is shown, and a new candidate medicine is provided for clinically treating the hepatic encephalopathy.

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.

The application discloses a kind of based on brain structure image's hepatic encephalopathy evaluation method and system, the method includes: obtaining the brain structure image data of subject brain;Based on brain structure image data, the feature parameter of characterizing brain tissue morphology is extracted;The characteristic parameter is handled by pre-training disease progression evaluation model, and the space-time progression trajectory of brain structure abnormality is inferred;Based on space-time progression trajectory, the disease subtype and disease progression stage to which the subject belongs are determined;Based on disease subtype and disease progression stage, evaluation information for characterizing the disease state of hepatic encephalopathy is generated.The space-time progression trajectory of brain structure abnormality is inferred based on cross-sectional image data, which overcomes the dependence on massive longitudinal tracking data, realizes the objective typing and staging of hepatic encephalopathy based on neurobiology, thereby effectively solving the technical problems of difficult to track disease evolution and individualized evaluation.

The invention discloses an application of an epoxidase type II inhibitor, the application is the application in preparation of drugs for treating liver injury, hepatitis, hepatic fibrosis, or liver function decline or complications thereof, and the application discovers that the existing COX-2 selective inhibitors such as celecoxib and the like and a novel efficient COX-2 selective inhibitor 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, the 2, 8-deuterated dimethyl-2-(trifluoromethyl)-2H-benzopyran-3-carboxylic acid disclosed by the invention has the effects of remarkably relieving liver injury, reducing necrosis focus and inflammatory cell infiltration of liver cells and resisting cholestatic hepatic fibrosis; in addition, hepatocyte lipid accumulation and ballooning induced by high fat diet can be reduced, and the progress of lipid hepatitis is remarkably inhibited; it is found for the first time that the traditional Chinese medicine composition can significantly reduce the concentration of serum bilirubin and play a role in relieving hyperbilirubinemia caused by liver injury or liver insufficiency; the traditional Chinese medicine composition can be used for treating neonatal jaundice, congenital bile duct atresia, cholestatic cirrhosis, acute toxic hepatic failure, bilirubin increase caused by acute attack of chronic hepatitis, chronic hepatic failure or hepatic encephalopathy and the like; therefore, the method has obvious economic benefit and clinical application value.

The present invention relates to the technical field of pharmaceuticals and specifically describes an application of a 5-hydroxytryptamine receptor 1A in preparing a drug for portal hypertension. The present invention achieved a significant decrease in portal venous pressure in model rats with cirrhotic portal hypertension by means of an HTR1A inhibitor WAY100635 administered at 1 mg / kg / day by intraperitoneal injection or alverine administered at 15 mg / kg / day by oral gavage. A 5-hydroxytryptamine receptor 1A antagonist can be used to prepare an experimental drug for the treatment of cirrhotic portal hypertension. Furthermore, the 5-hydroxytryptamine receptor 1A antagonist can also be used to prepare drugs for symptoms of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy. The present invention provides a novel treatment means to treat the manifestations of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy.

The invention discloses a portal vein stent shunt intraoperative blood flow proportion calculation method based on hemodynamics, and the method comprises the steps: obtaining target data which comprises target clinical measurement data and target image data after a target patient TIPS operation; calculating a target boundary condition based on the target data; constructing a target model, wherein the target model is a calculation model for calculating the blood mass flow rate based on geometric discretization and CFD simulation; and based on the target boundary condition and the target model, obtaining the blood proportion from the superior mesenteric vein and the spleen vein in the stent after the TIPS operation of the target patient. The blood proportion of the superior mesenteric vein and the splenic vein in the stent after the TIPS operation of the patient is calculated, and the difference of puncture from different branches of the portal vein in the TIPS operation is effectively judged, so that on the basis of effectively reducing the portal vein pressure, the occurrence of hepatic encephalopathy is reduced by optimizing the TIPS operation scheme.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and / or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.

Methods of treating hepatic encephalopathy and compounds and compositions useful therein are disclosed.

The invention discloses an SMV blood distribution calculation method and a postoperative hepatic encephalopathy risk assessment method, and relates to the technical field of medicines.The method comprises the steps that S1, CTA image data and ultrasonic data of a patient are obtained; s2, performing three-dimensional reconstruction on portal vein system dissection and a TIPS stent; s3, numerical simulation is completed; s4, quantitatively analyzing SMV blood distribution characteristics; s5, SMV blood distribution characteristics are obtained through SMV blood distribution calculation before the TIPS operation, the proportion of SMV blood flowing to the left portal vein branch and the right portal vein branch is analyzed, the position where the stent is implanted is selected, the proportion of SMV blood entering the TIPS stent after the operation is reduced, and the risk of hepatic encephalopathy of the patient after the TIPS operation is evaluated. According to the invention, the flow rule of the SMV blood in the portal vein system can be analyzed, and the volume ratio (percentage) of the SMV blood at any position can be obtained; the'blood ammonia hypothesis' is verified, and the estimation accuracy of the hepatic encephalopathy is improved.

A nanostructural sensing substrate includes indium tin oxide (ITO) film coated upstanding silicon nanowires (ITO / USNWs). The ITO / USNWs are fabricated by coating an ITO film on USNWs, the density of which has been reduced using a facile Ag-assisted chemical etching method. Furthermore, the bioreceptor modified ITO / USNWs are developed to serve as the sensing substrate of the EGFETs device for label-free diagnosis of biomarker related diseases, such as Alzheimer's disease (AD), acute myocardial infarction, coronary artery disease (CAD), hepatic encephalopathy, lung fibrosis, Cushing's syndrome and cancers. The ITO-coated-USNWs are also used in nano-featured cell based biosensors (CBB) for electrically quantitative evaluation of drug release.

The invention relates to application of sevelamer. The medicine is particularly applied to treatment of hepatic encephalopathy. According to the method for orally taking the sevelamer compound preparation, the level of ammonia in blood can be remarkably reduced to the normal level, bile acid in the intestinal tract is combined, system inflammation is reduced, and therefore the sevelamer compound preparation is beneficial to curing hepatic encephalopathy, and no obvious side effect is found; the sevelamer oral administration method provided by the invention has a remarkable treatment effect on hepatic encephalopathy, a new candidate treatment medicine is expected to be brought to clinical hepatic encephalopathy, and meanwhile, the range of indications of sevelamer in clinical treatment is widened.

The invention relates to the technical field of biology, and discloses an application of a plant extract in preparation of a medicine for treating hepatic encephalopathy, the plant extract is a mixture of curcumin and epigallocatechin gallate, and the plant extract activates oxidative stress by inhibiting or preventing TXNIP from passing through a PI3K / Akt signal channel, so that the hepatic encephalopathy can be treated. Further, the induction of excessive autophagy of astrocytes is prevented, so that the occurrence or development of hepatic encephalopathy is prevented. When the plant extract is used for treating hepatic encephalopathy, the curative effect of the medicine can be enhanced by adopting the plant extract, a new treatment thought is provided, and the plant extract has important significance for improving prognosis of patients.

Overt hepatic encephalopathy is a serious complication of cirrhosis and affects lipid and lipoprotein metabolism. The present invention relates to a biomarker for the prognosis of hepatic encephalopathy. The biomarker includes one or more of high-density lipoprotein cholesterol, model for end-stage liver disease score, age, gender, upper gastrointestinal bleeding, spontaneous bacterial peritonitis, overt hepatic encephalopathy grade, ascites, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol, serum creatinine, neutrophil-lymphocyte ratio, prothrombin time, and prothrombin activity level. Compared with patients with alcoholic hepatitis, liver disease, liver failure, etc. proposed in the prior art, due to the specificity of the target population, the biomarker proposed in this application can significantly improve the accuracy of the assessment of the prognosis of overt hepatic encephalopathy.

The invention discloses a hepatic encephalopathy recognition method, device and equipment based on metabolic ligation omics and a medium, and the method comprises the steps: S1, obtaining a metabolite data set; s2, high-difference connection screening is carried out; s3, screening key nodes; s4, drawing a reference mode; s5, individual connectivity omics quantification, and S6, mode recognition based on metabolic connectivity omics to solve the problems that in related technologies, due to the fact that the revealing strength of interaction between metabolites in a complex metabolic network is limited, understanding of network connectivity mode changes under different disease states is insufficient, metabolic connectivity of the individual level cannot be quantified, and the network connectivity is not quantified. And the objective property and the accuracy of the hepatic encephalopathy identification method are not enough.

The present disclosure relates to methods of treating or ameliorating hepatic encephalopathy (HE), including assessing the severity of HE in a patient suffering from HE, or the determining the presence or occurrence of an overt hepatic encephalopathy event. In particular, some aspects of the methods use a novel Hepatic Encephalopathy Staging Tool (HEST), which includes a set of criteria to categorize the HE into different stages and provide guidance on effective treatments based on the severity of the HE. Other aspects of the methods use an Overt Hepatic Encephalopathy Screening Tool (O-HEST) to determine whether an OHE event is occurring or has occurred and provide guidance on proper medical attention and change in treatment.

5′-O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

The invention provides a deep reinforcement learning method and a screening system for testing occult hepatic encephalopathy. The method comprises the following steps: preprocessing basic feature data of a test object; a training rule of a training model is set, the model is a deep Q network used for the occult hepatic encephalopathy test, and the training rule comprises a test state representation rule, an action space for executing or terminating the test, a reward function and a confidence coefficient system; the deep Q network is trained according to the preprocessed clinical data and the training rule, a model obtained through training is used for testing the occult hepatic encephalopathy, an implementation technology for balancing the contradictory relation among reliability, high efficiency and accuracy of a test result is established, and the problems that an occult hepatic encephalopathy test method is long in time consumption and high in efficiency are solved. The patient adaptability is low, and the accuracy is insufficient under various noise factors.

Gene therapy vectors, such as adeno-associated viruses (AAVs), designed for the treatment of mutations in the eukaryotic translation initiation factor 2B subunit epsilon (EIF2B5) gene are provided. The EIF2B5 gene provides instructions for making one of the five subunits of the eIF2B protein, specifically the epsilon subunit of the protein. Such mutations are associated with diseases or disorders such as leukoencephalopathy, macrocephalic leukoencephalopathy, leukodystrophy, stroke, migraine, epilepsy, multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD), astrogliosis in aging, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Alexander disease, hepatic encephalopathy (HE), Aicardi-Goutières syndrome, CLC-2-associated disease, oculodentodigital dysplasia, and / or giant axonal neuropathy. Such leukoencephalopathy or leukodystrophies include, but are not limited to, vanishing white matter (VWM). The disclosed gene therapy vector provides EIF2B5 cDNA to a subject in need, which results in the expression of wild-type or functional EIF2B5 protein. Also provided is a new promoter, designated gfa1405, designed to target astrocytes and neurons. Thus, compositions, nanoparticles, extracellular vesicles, exosomes, or vectors comprising the gfa1405 promoter, and methods of use thereof are also provided.

The utility model discloses a retention enema device special for hepatic encephalopathy. The air bag assembly comprises a balloon, a ventilation sleeve, an inflation tube and an inflation air bag, the balloon is an annular balloon body and comprises an outer ring wall and an inner ring wall, the elasticity of the inner ring wall is small, and the elasticity of the outer ring wall is large; an air injection channel is arranged in the ventilation sleeve, one side of the inner ring wall is opened, the air injection channel is communicated with the opening of the inner ring wall, and the balloon and the ventilation sleeve are sleeved on the liquid injection tube; the inflation air bag is communicated with the air injection channel through an inflation pipe, an air release valve and a one-way air valve are arranged on the inflation pipe, the one-way air valve is arranged between the inflation air bag and the air release valve, and an air inlet valve is arranged on the inflation air bag. One end of the liquid injection tube is provided with an enema inlet, the liquid injection tube is provided with a branch tube, the branch tube is provided with a medicine injection port, and the other end of the liquid injection tube is a hose. The position of the enema device can be fixed in the enema process, liquid leakage at the anus of a patient is prevented, the comfort level of the patient is improved, and the accuracy of the enema process is guaranteed.

The invention discloses a blood mixing degree calculation method and a postoperative hepatic encephalopathy prediction method, and belongs to the technical field of medicines.The method comprises the following steps that S1, CTA image data and ultrasonic data of a patient are obtained; s2, performing three-dimensional reconstruction on portal vein system dissection and a TIPS stent; s3, numerical simulation is completed; s4, quantitatively analyzing the portal vein blood mixing degree; and S5, calculating the blood mixing degree of the patient before the TIPS operation to obtain a portal vein blood mixing degree characteristic which is used for predicting the occurrence risk of hepatic encephalopathy after the TIPS operation so as to assist in clinical decision making. According to the method, the mixing degree of the blood in the portal vein can be quantitatively analyzed, the method is more accurate compared with a traditional qualitative method which depends on portal vein radiography for observation and judgment, the postoperative hepatic encephalopathy risk is estimated by analyzing the mixing degree of the portal vein blood before the TIPS operation, and then TIPS operation treatment of a patient with the high hepatic encephalopathy risk is avoided.

Methods of treating hepatic encephalopathy and compounds and compositions useful therein are disclosed.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and / or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.

Acute decompensation (AD) of cirrhosis is defined by the acute development of ascites, gastrointestinal haemorrhage, hepatic encephalopathy or infection. The PREDICT study distinguishes three different phenotypic sub-types in patients with AD but without ACLF according to hospital readmission and development of ACLF: stable decompensated cirrhosis, unstable decompensated cirrhosis and pre-ACLF group. Predicting the phenotypes in patients with AD would thus be useful, since mortality rates vary considerably between the three phenotypes. This will allow us a better management of patients with AD. Now the inventors used proteomics analysis of proteins carried by plasma lEVs to identify novel EV protein biomarkers having higher concentrations in the plasma of patients who will develop organ failure than in those who will not (Tenascin C and 0LFM4 lEVs). Moreover, the inventors identified 2 plasma lEVs (FCGBP and Tenascin C) predicting survival in PREDICT. Tenascin C was the most robust one since also predicting survival in ACLARA. Accordingly, the present invention relates to large extracellular vesicles as biomarkers for predicting organ failures and survival time of patients suffering from an acute decompensation of cirrhosis.

The dominant hepatic encephalopathy is a serious complication of liver cirrhosis and affects lipid and lipoprotein metabolism. The invention relates to a biomarker for prognosis of hepatic encephalopathy. The biomarkers comprise high-density lipoprotein cholesterol, an end-stage liver disease model score, age, gender, upper gastrointestinal hemorrhage, spontaneous bacterial peritonitis, dominant hepatic encephalopathy grading, ascites, aspartic transaminase, glutamic-pyruvic transaminase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol and serum creatinine. The specific value of neutrophil to lymphocyte, the prothrombin time and the prothrombin activity level are one or more. Compared with patients with alcoholic hepatitis, liver diseases, hepatic failure and the like in the prior art, the marker provided by the invention can remarkably improve the evaluation accuracy of the prognosis of the dominant hepatic encephalopathy due to the specificity of people.

The invention relates to the technical field of biology, in particular to a metabolic marker for screening hepatic encephalopathy and application of the metabolic marker. The invention discloses a tryptophan composition. The tryptophan composition comprises tryptophan, kynurenine and quinolinic acid. The tryptophan composition is used for screening hepatic encephalopathy, and has the characteristics of high sensitivity and good specificity.